Pharmacological action

Enzyme tool. Represents the methods of genetic engineering deoxyribonuclease I. Cleaves the extracellular DNA, contained in large quantities in the viscous bronchial secretion which accumulates in the airways in cystic fibrosis patients. Reduces the viscosity of sputum, thereby improving lung function and reducing the risk of infectious diseases in these patients.


In the combined therapy of cystic fibrosis with a decrease in forced vital lung capacity less than 40% of the physiological norm.

Dosage regimen

For adults and children older than 5 years of daily dose is 2.5 mg in 1 device. In some cases, patients older than 21 can be applied in a dose of 2.5 mg 2 times / day.

Side effect

Perhaps: pharyngitis, voice alteration.

Rare: laryngitis, skin rash, itching, hives.


Hypersensitivity to dornaze alpha.

Application of pregnancy and breastfeeding

When pregnancy is used only on strict indications. Not recommended for use during lactation.


Exacerbation of infectious diseases during the period of dornazy alpha is not grounds for termination of therapy.

Data on the efficacy and safety of children under 5 years and / or patients with reduced forced vital capacity by more than 40%, no.

Not to be confused in the inhaler with other drugs.